HBM Healthcare Investments (SIX: HBMN)

Last close As at 24/05/2024


4.00 (1.97%)

Market capitalisation


HBMN aims to generate long-term capital gains through direct investments in emerging private and public companies in biotechnology, human medicine, diagnostics, medical technology and related areas.

Latest Insights

View More

Investment Companies | Review

HBM Healthcare Investments — Looking ahead to renewed opportunities

Investment Companies | Review

HBM Healthcare Investments — A stellar year to mark 20th anniversary

Investment Companies | Flash note

HBM Healthcare Investments — Top 10 holding Viela Bio to be taken out for $3bn

Investment Companies | Review

HBM Healthcare Investments — Keeping calm amid the market turmoil

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (1.0) (12.1) (14.5)
Relative (6.0) (12.4) (9.3)
52 week high/low €275.0/€192.2


HBM Healthcare Investments (HBMN) posted its first NAV loss in a decade for FY22 (ended 31 March), but, as shown in the chart below, its long-term performance record remains very impressive. The recent fall in the share price from a premium to a discount to NAV (10.0% at 20 May) could present an opportunity for long-term investors who, like HBMN’s management team, remain convinced of the long-term opportunities afforded by careful investment in the healthcare and biotechnology space. HBMN is unusual among its peers in offering a portfolio made up of private companies, listed equities and funds, broadly spread by geography and clinical focus, with a high distribution policy (current yield of 3.8%).



Investment Companies

UK stock market – Scope for further upside in UK large-cap stocks


Investment Companies

Listed private equity – Performing a balancing act


Investment Companies

European equities


Investment Companies

Listed Private Equity

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free